SYFOVRE: Approximately $155 million and $587 million in preliminary U.S. net product revenues in the fourth quarter and full year 2025, respectively. EMPAVELI: Approximately $35 million and $102 million in preliminary U.S. net product revenues in the fourth quarter and full year 2025, respectively.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis price target lowered to $48 from $55 at Stifel
- Apellis Pharmaceuticals: Buy Rating Affirmed Amidst European Regulatory Milestones and Long-term Growth Potential
- Roth Capital healthcare analyst holds an analyst/industry conference call
- Buy Rating for Apellis Pharmaceuticals: Strong Empaveli Launch and Long-term Syfovre Potential
- Apellis announces NEJM published ‘positive’ Phase 3 EMPAVELI study data